Q-omics provides the consensus-scored MYO15B profile across patient tissues and cancer cell-line models. MYO15B expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, MYO15B is differentially expressed in 14, with the highest sampling consensus in KICH. Additionally, MYO15B RNA expression shows 18,770 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KICH, and UVM as cancer lineages where MYO15B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MYO15B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MYO15B survival associations across molecular data types. MYO15B RNA expression shows survival associations in the most cancer types (23), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MYO15B RNA expression–survival associations across cancer types. High MYO15B expression shows unfavorable associations in ACC and LGG, but favorable associations in HNSC, BLCA, BRCA and KIRP. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for MYO15B RNA expression.
This table summarizes MYO15B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MYO15B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MYO15B shows lower tumor expression in KICH, LUSC, UCEC and BRCA and higher tumor expression in KIRC and LIHC. The KICH box plot shows higher MYO15B RNA expression in normal versus tumor tissue (log2 FC = −2.280, t-test p < 0.001).
This table shows molecular features associated with MYO15B in patient tissues and cancer cell lines. In patient samples, MYO15B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, MYO15B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
